A Randomized, open labeled, comparative , parallel group, multicentric trial to evaluate the efficacy and safety of the proposed fixed dose combination of Tramadol 50 mg IR + Diclofenac 75 mg SR vs standard / approved fixed dose combination of Tramadol 37.5 mg + Paracetamol 325 mg in treatment of patients with moderate to severe pain due to acute musculoskeletal conditions , acute flare of osteoarthritis , acute flare of rheumatoid arthritis and post operative pain

Trial Profile

A Randomized, open labeled, comparative , parallel group, multicentric trial to evaluate the efficacy and safety of the proposed fixed dose combination of Tramadol 50 mg IR + Diclofenac 75 mg SR vs standard / approved fixed dose combination of Tramadol 37.5 mg + Paracetamol 325 mg in treatment of patients with moderate to severe pain due to acute musculoskeletal conditions , acute flare of osteoarthritis , acute flare of rheumatoid arthritis and post operative pain

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Diclofenac/tramadol (Primary) ; Tramadol/paracetamol (Primary)
  • Indications Acute pain; Musculoskeletal pain; Postoperative pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 Status changed from recruiting to completed.
    • 29 Mar 2015 Results presented at the 2015 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 08 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top